

# Composite grading algorithm for the National Cancer In Outcomes version of the Common Terminology Criteria

Clinical Trials

18, 104-114

DOI: 10.1177/1740774520975120

Citation Report

#	ARTICLE	IF	CITATIONS
1	Early discontinuation and dose reduction of adjuvant chemotherapy in stage III colon cancer patients. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110063.	3.2	5
2	Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial. Dermatology and Therapy, 2021, 11, 1319-1332.	3.0	23
4	Understanding Treatment Tolerability in Older Adults With Cancer. Journal of Clinical Oncology, 2021, 39, 2150-2163.	1.6	33
5	A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177â€“labeled Prostate-specific Membrane Antigenâ€“targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer. European Urology, 2021, 80, 82-94.	1.9	53
6	Evaluating Treatment Tolerability Using the Toxicity Index With Patient-Reported Outcomes Data. Journal of Pain and Symptom Management, 2022, 63, 311-320.	1.2	5
7	SYMptom monitoring with Patient-Reported Outcomes using a web application among patients with Lung cancer in the Netherlands (SYMPRO-Lung): study protocol for a stepped-wedge randomised controlled trial. BMJ Open, 2021, 11, e052494.	1.9	9
8	Transperitoneal versus extraperitoneal laparoscopic aortic lymph nodal staging for locally advanced cervical cancer: A systematic review and meta-analysis. European Journal of Surgical Oncology, 2021, 47, 2256-2264.	1.0	7
9	Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. Journal of Clinical Oncology, 2021, 39, 3140-3148.	1.6	72
10	Assessing concordance between patient-reported and investigator-reported CTCAE after proton beam therapy for prostate cancer. Clinical and Translational Radiation Oncology, 2021, 31, 34-41.	1.7	4
11	Clinical Characteristics and Treatment Response With Checkpoint Inhibitors in Malignant Melanoma of the Vulva and Vagina. Journal of Lower Genital Tract Disease, 2021, 25, 146-151.	1.9	12
12	Rheumatological Adverse Events of Cancer Therapy with Immune Checkpoint Inhibitors. Archives of Medical Research, 2022, 53, 113-121.	3.3	2
14	The Efficacy and Safety of Remimazolam Tosilate versus Etomidate-Propofol in Elderly Outpatients Undergoing Colonoscopy: A Prospective, Randomized, Single-Blind, Non-Inferiority Trial. Drug Design, Development and Therapy, 2021, Volume 15, 4675-4685.	4.3	33
15	Reconsidering tolerability of cancer treatments: opportunities to focus on the patient. Supportive Care in Cancer, 2022, 30, 3661-3663.	2.2	4
16	eSyM: An Electronic Health Recordâ€“Integrated Patient-Reported Outcomesâ€“Based Cancer Symptom Management Program Used by Six Diverse Health Systems. JCO Clinical Cancer Informatics, 2022, 6, e2100137.	2.1	19
17	Retrospective analysis of clinical trial safety data for pembrolizumab reveals the effect of co-occurring infections on immune-related adverse events. PLoS ONE, 2022, 17, e0263402.	2.5	7
18	Strategies to Mitigate Chemotherapy and Radiation Toxicities That Affect Eating. Nutrients, 2021, 13, 4397.	4.1	9
20	LITE SABR M1: A phase I trial of Lattice stereotactic body radiotherapy for large tumors. Radiotherapy and Oncology, 2022, 167, 317-322.	0.6	10
21	Effect of Autologous Stem Cell Transplantation Combined with Modified VTD Regimen on Elderly Patients with Multiple Myeloma and Its Influence on miRNA Cytokines. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-8.	1.3	3

#	ARTICLE	IF	CITATIONS
22	Blocking EGFR with nimotuzumab: a novel strategy for COVID-19 treatment. Immunotherapy, 2022, 14, 521-530.	2.0	17
23	Persistent symptoms of fatigue, neuropathy and role of functioning impairment among indolent <scp>non-Hodgkin</scp> lymphoma survivors: A longitudinal <scp>PROFILES</scp> registry study. British Journal of Haematology, 2022, 197, 590-601.	2.5	6
24	Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial. BMJ, The, 2021, 375, e066588.	6.0	16
25	Financial Hardship and Quality of Life Among Patients With Advanced Cancer Receiving Outpatient Palliative Care. Cancer Nursing, 2023, 46, 3-13.	1.5	2
26	High-Dose Dexamethasone Versus Tocilizumab in Moderate to Severe COVID-19 Pneumonia: A Randomized Controlled Trial. Cureus, 2021, 13, e20353.	0.5	10
27	Efficacy and Safety of Docetaxel and Sodium Cantharidinate Combination vs. Either Agent Alone as Second-Line Treatment for Advanced/Metastatic NSCLC With Wild-Type or Unknown EGFR Status: An Open-Label, Randomized Controlled, Prospective, Multi-Center Phase III Trial (Cando-L1). Frontiers in Oncology, 2021, 11, 769037.	2.8	1
28	Electronic Patient Symptom Management Program to Support Patients Receiving Cancer Treatment at Home During the COVID-19 Pandemic. Value in Health, 2022, 25, 931-936.	0.3	7
29	Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematology, the, 2022, 9, e374-e384.	4.6	11
30	Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant. Transplantation and Cellular Therapy, 2022, 28, 473-482.	1.2	20
31	Longitudinal Collection of Patient-Reported Outcomes and Activity Data during CAR-T Therapy: Feasibility, Acceptability, and Data Visualization. Cancers, 2022, 14, 2742.	3.7	6
32	A Narrative Review on the Collection and Use of Electronic Patient-Reported Outcomes in Cancer Survivorship Care with Emphasis on Symptom Monitoring. Current Oncology, 2022, 29, 4370-4385.	2.2	14
33	Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial. Journal of Bone Oncology, 2022, 35, 100441.	2.4	9
34	Conventional Laparoscopy versus Robotic-Assisted Aortic Lymph-Nodal Staging for Locally Advanced Cervical Cancer: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2022, 11, 3332.	2.4	10
35	Evaluation of the patient experience of symptomatic adverse events on Phase I clinical trials using PRO-CTCAE. British Journal of Cancer, 2022, 127, 1629-1635.	6.4	3
36	Using the Pediatric Patient-reported Outcomes "common Terminology Criteria for Adverse Events to Longitudinally Measure Symptom Adverse Events of Children With Advanced Cancer. Cancer Care Research Online, 2022, 2, e020.	0.5	2
37	Remote Symptom Monitoring of Patients With Cancer Undergoing Radiation Therapy. Cureus, 2022, , .	0.5	0
38	The Discordance between Patient- and Clinician Reported Outcomes During (Chemo-)Radiation Therapy for Lung Cancer. SSRN Electronic Journal, 0, , .	0.4	0
39	Pretreatment Nutritional Status in Combination with Inflammation Affects Chemotherapy Interruption in Women with Ovarian, Fallopian Tube, and Peritoneal Cancer. Nutrients, 2022, 14, 5183.	4.1	0

#	ARTICLE	IF	CITATIONS
40	Selecting a PRO-CTCAE-based subset for patient-reported symptom monitoring in prostate cancer patients: a modified Delphi procedure. ESMO Open, 2023, 8, 100775.	4.5	1
41	Wearable sensor-based performance status assessment in cancer: A pilot multicenter study from the Alliance for Clinical Trials in Oncology (A19_Pilot2). , 2023, 2, e0000178.		3
42	A toolbox of different approaches to analyze and present PRO-CTCAE data in oncology studies. Journal of the National Cancer Institute, 2023, 115, 586-596.	6.3	1
43	A cross-sectional study of patient-reported outcomes and symptom burden using PROMIS and PRO-CTCAE measures in light chain amyloidosis. Quality of Life Research, 2023, 32, 1807-1817.	3.1	3
44	Surveillance of Symptom Burden Using the Patient-Reported Outcome Version of the Common Terminology Criteria for Adverse Events in Patients With Various Types of Cancers During Chemoradiation Therapy: Real-World Study. JMIR Public Health and Surveillance, 0, 9, e44105.	2.6	2
46	An Unsupervised Machine Learning Approach to Evaluating the Association of Symptom Clusters With Adverse Outcomes Among Older Adults With Advanced Cancer. JAMA Network Open, 2023, 6, e234198.	5.9	4
47	Methadone rotation versus other opioid rotation for refractory cancer induced bone pain: protocol of an exploratory randomised controlled open-label study. BMC Palliative Care, 2023, 22, .	1.8	1
48	Remote Activity Monitoring and Electronic Patient-Reported Outcomes Collection During Radiotherapy for Head and Neck Cancer: A Pilot Study. JCO Clinical Cancer Informatics, 2023, , .	2.1	0
49	Assessing the impact of digital patient monitoring on health outcomes and healthcare resource usage in addition to the feasibility of its combination with at-home treatment, in participants receiving systemic anticancer treatment in clinical practice: protocol for an interventional, open-label, multicountry platform study (ORIGAMA). BMJ Open, 2023, 13, e063242.	1.9	2
50	Outcome Measures and Patient-Reported Metrics in Cancer Rehabilitation. Current Oncology Reports, 0, , .	4.0	2
53	Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048). Journal of Clinical Oncology, 2023, 41, 3724-3734.	1.6	28
54	Evaluating Nurses' Time to Response by Severity and Cancer Stage in a Remote Symptom Monitoring Program for Patients With Breast Cancer. JCO Clinical Cancer Informatics, 2023, , .	2.1	1
55	Treatment effectiveness and side effects of patients with hepatitis C in the prisons of Southern Taiwan: a real-life retrospective analysis. BMJ Open, 2023, 13, e070490.	1.9	0
56	Patient-reported Adverse Events During Neoadjuvant Therapy in a Phase 2 Borderline Resectable Pancreatic Cancer Clinical Trial (Alliance A021501). Annals of Surgery, 2023, 278, 598-608.	4.2	1
57	Using a chatbot to reduce emergency department visits and unscheduled hospitalizations among patients with gynecologic malignancies during chemotherapy: A retrospective cohort study. Heliyon, 2023, 9, e15798.	3.2	1
58	Pharmacokinetic Properties of Dapagliflozin in Hemodialysis and Peritoneal Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2023, 18, 1051-1058.	4.5	5
59	A tailored phase I-specific patient-reported outcome (PRO) survey to capture the patient experience of symptomatic adverse events. British Journal of Cancer, 0, , .	6.4	0
60	The PRO-RCC study: a long-term PROspective Renal Cell Carcinoma cohort in the Netherlands, providing an infrastructure for "Trial within Cohorts"™ study designs. BMC Cancer, 2023, 23, .	2.6	0

#	ARTICLE	IF	CITATIONS
61	A multi-method approach to selecting PRO-CTCAE symptoms for patient-reported outcome in women with endometrial or ovarian cancer undergoing chemotherapy. <i>Journal of Patient-Reported Outcomes</i> , 2023, 7, .	1.9	1
62	An eHealth App (CAPABLE) Providing Symptom Monitoring, Well-Being Interventions, and Educational Material for Patients With Melanoma Treated With Immune Checkpoint Inhibitors: Protocol for an Exploratory Intervention Trial. <i>JMIR Research Protocols</i> , 0, 12, e49252.	1.0	2
63	Testing a Model of Care for Patients on Immune Checkpoint Inhibitors Based on Electronic Patient-Reported Outcomes: Protocol for a Randomized Phase II Controlled Trial. <i>JMIR Research Protocols</i> , 0, 12, e48386.	1.0	0
64	Study protocol of a phase II clinical trial evaluating the efficacy of neoadjuvant intraperitoneal and systemic albumin-bound paclitaxel combined with camrelizumab and S-1 in the treatment of patients with exfoliative cell-positive gastric cancer. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
65	Adverse event signal extraction from cancer patientsâ€™ narratives focusing on impact on their daily-life activities. <i>Scientific Reports</i> , 2023, 13, .	3.3	0
68	Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel. <i>Cancers</i> , 2023, 15, 4711.	3.7	2
69	The course of self-perceived cognitive functioning among patients with lymphoma and the co-occurrence with fatigue and psychological distress. <i>Journal of Cancer Survivorship</i> , 0, , .	2.9	0
70	High endothelial venules predict response to PD-1 inhibitors combined with anti-angiogenesis therapy in NSCLC. <i>Scientific Reports</i> , 2023, 13, .	3.3	0
71	Prospective analysis of patientâ€™reported outcomes and physicianâ€™reported outcomes with gynecologic cancer chemotherapy. <i>Journal of Obstetrics and Gynaecology Research</i> , 2024, 50, 75-85.	1.3	0
73	Development and validation of the chemotherapy-induced peripheral neuropathy integrated assessment â€œ oxaliplatin subscale: a prospective cohort study. <i>BMC Cancer</i> , 2023, 23, .	2.6	0
74	A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen. - PATROL-I. <i>Investigational New Drugs</i> , 2024, 42, 44-52.	2.6	0
75	Use of the National Cancer Institute Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events to assess treatment tolerability in pulmonary arterial hypertension: qualitative patient research findings in current and former users of oral selexipag. <i>Journal of Patient-Reported Outcomes</i> , 2023, 7, .	1.9	0
76	Electronic Patient-Reported Outcomes in Oncology: Lessons from Six Cancer Centers. <i>NEJM Catalyst</i> , 2024, 5, .	0.7	0
77	Effect of homeâ€based resistance training on chemotherapy relative dose intensity and tolerability in colon cancer: The FORCE randomized control trial. <i>Cancer</i> , 2024, 130, 1858-1868.	4.1	0
78	Predictors of sleep quality components in patients undergoing transarterial chemoembolisation: a cross-sectional study. <i>Supportive Care in Cancer</i> , 2024, 32, .	2.2	0
79	Development and initial validation of the <sc>ALâ€PROFILE</sc> patientâ€™reported outcome measure in light chain (<sc>AL</sc>) amyloidosis. <i>European Journal of Haematology</i> , 2024, 112, 900-909.	2.2	0
80	Surgery combined with anlotinib for local control of patients with resectable extremity desmoid fibromatosis: a retrospective study. <i>Frontiers in Pharmacology</i> , 0, 15, .	3.5	0